Patents Issued in May 7, 2020
-
Publication number: 20200138689Abstract: Provided are personal care compositions including (a) hydrophobic ester oil, (b) at least one of a nonionic or anionic surfactant, and (c) one or more polymers containing polymerized structural units of (i) 79 to 95.74 weight % of C4-C8 (meth)acrylate monomers, (ii) 0.5 to 5 weight % of (meth)acrylic acid monomer, (iii) 3.75 to 14 weight % of (methoxy) poly(ethylene glycol) methacrylates, and (iv) 0.01 to 2 weight % of at least one crosslinker.Type: ApplicationFiled: June 13, 2018Publication date: May 7, 2020Inventors: Lu Bai, Liang Chen, Yunshen Chen, Shannon Golden, Jennifer Koenig, Lyndsay M. Leal, Xiang Qian Liu, Wen-Shiue Young, Fanwen Zeng
-
Publication number: 20200138690Abstract: The present invention relates to a cosmetic composition comprising a physiologically acceptable medium, in the form of an oil-in-water emulsion, containing at least one associative polyurethane complying with formula (I) and pigment and/or nacre particles coated with at least one lipophilic compound, the average size of said particles being greater than 100 nm.Type: ApplicationFiled: January 7, 2020Publication date: May 7, 2020Inventors: Gaëlle BRUN, Annick Collette, Elodie Valverde, Anne-Marie Lezoray
-
Publication number: 20200138691Abstract: Provided is a water-in-oil type cosmetic including: an oil agent having a melting point of 20° C. or lower; a silicone gel; a modified silicone surfactant having a hydrophile-lipophile balance value of less than 6; inorganic particles of at least one selected from the group consisting of titanium oxide, iron oxide, and mica; water; and a co-emulsifier, in which the oil agent having a melting point of 20° C. or lower contains 60% by mass or greater of silicone oil, a content of the modified silicone surfactant having a hydrophile-lipophile balance value of less than 6 is greater than 0.1% by mass and less than 1% by mass with respect to a total amount of the water-in-oil type cosmetic, and the inorganic particles of at least one selected from the group consisting of titanium oxide, iron oxide, and mica are contained in an oil phase.Type: ApplicationFiled: November 20, 2019Publication date: May 7, 2020Inventors: Katsuhiko KANAZAWA, Mayuko SUZUKI, Ikuko OHGARU, Toshiaki KUBO
-
Publication number: 20200138692Abstract: The invention relates to a composition comprising: (i) a trialkylsiloxysilylcarbamoyl pullulan compound, (ii) a polymethyl methacrylate polymer, (iii) a mattifying substance, and (iv) at least one volatile hydrocarbon oil. The invention is also targeted at the use of such a composition for making up and/or caring for keratinous substances, the skin and the lips, and more particularly in mascaras, foundations and lipsticks.Type: ApplicationFiled: December 13, 2018Publication date: May 7, 2020Inventors: Yohann BICHON, Caroline KOUSSOUROS
-
Publication number: 20200138693Abstract: Hair composition, especially for conditioning hair, is provided, which comprising: (i) at least one cationic surfactant of the formula (I), wherein: R1 to R4, identical or different, represent a linear or branched aliphatic group comprising from 1 to 30 carbon atoms, an aromatic group such as aryl or alkylaryl, at least one of the groups R1 to R4 comprising from 8 to 30 carbon atoms, and X? is an anionic counterion chosen from halides, (ii) an oil-in-water emulsion having D50 particle size of less than 350 nm and comprising: a silicone mixture comprising (i) a trialkylsilyl terminated dialkylpolysiloxane having a viscosity of from 40,000 to less than 100,000 mPa·s at 25° C. and (ii) an amino-silicone having a viscosity of from 1,000 to 15,000 mPa·s at 25° C.Type: ApplicationFiled: May 31, 2017Publication date: May 7, 2020Applicant: L'OREALInventors: Hui LIU, Wi-Soon CHIA, Maxime DE BONI
-
Publication number: 20200138694Abstract: The application describes a cosmetic method for the chemical treatment of keratinic fibers, in which i. a cosmetic composition is applied as a pretreatment agent to keratinic fibers, and ii. the keratinic fibers are subjected to a chemical treatment with an oxidizing agent and/or a reducing agent within a period of from about 5 seconds to about 24 hours after step i., wherein the cosmetic composition, based on its total weight, comprises from about 0.01 to about 4.00% by weight of a polyorganosiloxane of the formula (I) The damage to the keratinic fibers due to the oxidizing and/or reducing agents can be reduced by using the special pretreatment agent.Type: ApplicationFiled: November 6, 2019Publication date: May 7, 2020Applicant: Henkel AG & Co. KGaAInventor: ERIK SCHULZE ZUR WIESCHE
-
Publication number: 20200138695Abstract: Provided is a cosmetic composition that maintains high stability and restrains from becoming cloud. This cosmetic composition is prepared by including (A) polyoxyethylene polyoxypropylene glycol, and (B) an amino acid based surfactant having, in a single molecule thereof, two or more hydrophobic groups and two or more hydrophilic groups. Furthermore, provided is a method of giving a cloudiness-restraining effect to a cosmetic composition, including causing the component (A) and the component (B) to coexist with each other in the cosmetic composition.Type: ApplicationFiled: March 7, 2018Publication date: May 7, 2020Inventors: Junichi FUJIMOTO, Phat Thanh PHAN
-
Publication number: 20200138696Abstract: A process for the production of a solid cosmetic preparation is described wherein a wax phase comprising at least one wax, at least one oil, and if applicable, oil-soluble ingredients and solvents are melted, the molten wax phase is mixed with an aqueous phase comprising at least one water-soluble or water-soluble water-dispersible film former and with a w/o emulsifying system until an emulsion is formed, and the resulting emulsion is allowed to cool to form a wax matrix with aqueous phase droplets embedded therein, and the products made therefrom and their use.Type: ApplicationFiled: December 28, 2017Publication date: May 7, 2020Inventors: Ingolf KAHLE, Simona LEBOK, Christian SPROGAR
-
Publication number: 20200138697Abstract: Provided herein are, inter alia, methods of treating, repairing, mitigating, and/or reducing the incidence, size or visibility of white spot lesions on teeth by administering oral care compositions comprising partially hydrolyzed plant protein.Type: ApplicationFiled: April 24, 2018Publication date: May 7, 2020Inventors: LaTonya KILPATRICK-LIVERMAN, Jianhong QIU, Thomas SUBKOWSKI, Stefan JENEWEIN, Marvin KAROS, Claus BOLLSCHWEILER, Nina SCHNEIDER, Ralph Peter SANTARPIA, III, Volker WENDEL
-
Publication number: 20200138698Abstract: Disclosed are a scrub sponge and a preparation method therefor. The method for preparing the scrub sponge includes the operations of: obtaining a first mixture by stirring alkalizer, porogen, konjac powder, scrub granule and water, and filling the first mixture into a mold to form a preform, where the preform includes a first sponge layer; forming a parison by sequentially cooking and freezing the preform; and sequentially unfreezing, dehydrating and drying the parison to obtain the scrub sponge.Type: ApplicationFiled: December 19, 2019Publication date: May 7, 2020Inventors: Xiaojun WANG, Huaixin CHEN, Qisheng PAN
-
Publication number: 20200138699Abstract: Disclosed is a method of exfoliating skin. The method can include topically applying an effective amount of a composition to skin in need thereof. The composition can include an alpha hydroxy acid, 4-tert-butylcyclohexanol, an aqueous extract of plankton comprising an exopolysacchride synthesized by Vibo alginolyticus, an aqueous extract of Phragmites communis, an aqueous extract of Poria cocos, and an aqueous extract of Cucurbita pepo (pumpkin) seed.Type: ApplicationFiled: August 20, 2019Publication date: May 7, 2020Inventors: David GAN, Geetha KALAHASTI, Lisha VANPELT
-
Publication number: 20200138700Abstract: Hypotonic microbicidal compositions including an antimicrobial, such as an antiviral compound, and a pharmaceutically acceptable carrier in a solution formulation having hypotonic osmolarity have been developed for administration rectally to the gastrointestinal mucosa. In a preferred embodiment for use in preventing or decreasing HIV infection, the microbicidal is tenofovir, or a prodrug or derivative thereof. The formulations may include additional agents such as surfactants to enhance cleansing, buffers, or preservatives. Polymers may be included for osmolarity as well as comfort.Type: ApplicationFiled: December 17, 2019Publication date: May 7, 2020Inventors: Katharina Maisel, Craig W. Hendrix, Laura Ensign, Edward Fuchs, Richard Cone, Justin Hanes
-
Publication number: 20200138701Abstract: A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye.Type: ApplicationFiled: March 21, 2019Publication date: May 7, 2020Applicant: Mati Therapeutics Inc.Inventors: Steven A. Odrich, Liane C. Glazer
-
Publication number: 20200138702Abstract: Provided is a smart contact lens for non-invasive drug delivery including a platform configured to be worn on an eye, a reservoir installed within the platform, and having a receiving part in which a drug is received, to provide the eye with the drug, an electrode for iontophoresis installed in the reservoir to make iontophoresis work, to provide the eye with the drug from the reservoir, and an activation chip electrically connected to the electrode for iontophoresis to activate iontophoresis.Type: ApplicationFiled: November 4, 2019Publication date: May 7, 2020Inventors: Jinseok KIM, Yong-Won SONG, Hyungdal PARK, Ockchul KIM
-
Publication number: 20200138703Abstract: Provided herein is a storage stable non-fluoride toothpaste composition enriched with a dietary supplement containing both oil soluble and water soluble vitamins. The dietary supplement is incorporated into the toothpaste, the dietary supplement containing a water soluble vitamin portion including at least one water soluble vitamin and an oil soluble vitamin portion. The oil soluble vitamin portion includes at least one oil soluble vitamin, a carrier oil and an emulsifier. The toothpaste is thereby formulated in a manner such that oral application will result in systemic delivery of at least a portion of the dietary supplement to meet a 2% RDI threshold even when 3 or less serving sizes are orally applied.Type: ApplicationFiled: September 27, 2019Publication date: May 7, 2020Inventor: Bruce Alan Golden
-
Publication number: 20200138704Abstract: A method of making a gummy composition, comprising providing a gelatin blend, comprising gelatin and a swelling agent, providing a bonding blend, comprising a combination of at least two of a monosaccharide, a disaccharide and a tri-saccharide, providing an active blend, comprising an active agent and a liquid solvent, wherein the liquid solvent comprises a diprotic solvent, tri-protic solvent, or a combination thereof, combining the active blend, the bonding blend and a gelatin blend to provide a molding blend, and forming the molding blend into a gummy compositionType: ApplicationFiled: June 20, 2018Publication date: May 7, 2020Inventors: Feng Wan, William Brenden Carlson
-
Publication number: 20200138705Abstract: A method of making a gummy composition, comprising providing a gelling blend, comprising pectin having a carboxyl content of not more than 45% by weight of pectin and an amide content of not less than 20% by weight of pectin, a solubilizing blend, a swelling solvent and optionally a first bonding blend; optionally providing an emulsifying blend; optionally providing a second bonding blend, wherein the first bonding blend and the second bonding form a bonding blend; optionally providing an active blend, comprising an active agent; combining the gelling blend, the surfactant blend, the bonding blend and the active blend to provide a pre-molding blend, combing the pre-molding blend with a pH adjusting blend to provide a molding blend, wherein the molding blend has a pH value at least about 5; and forming the molding blend into a gummy composition.Type: ApplicationFiled: June 20, 2018Publication date: May 7, 2020Inventors: Feng Wan, William Brenden Carlson
-
Publication number: 20200138706Abstract: The present invention relates to nicotine-containing chewing gum compositions and the method of preparing the same. The present invention provides improved and stable nicotine-containing chewing gum compositions for use in nicotine replacement therapy, which provide rapid nicotine release in the oral cavity and effectively satisfy the craving that most smokers experience.Type: ApplicationFiled: May 16, 2018Publication date: May 7, 2020Applicant: Enorama Pharma ABInventors: Varma RUDRARAJU, Yelchuri RAJESH
-
Publication number: 20200138707Abstract: The present invention provides, in some aspects, bilayered and trilayered pharmaceutical implant compositions for the unidirectional delivery of anti-cancer compounds to the brain over a period of time (e.g., several weeks, 1, 2, 3, 4, 5, 6, 7 days, or 1, 2, 3, weeks, or any range derivable therein) following the removal of glioblastoma multiforme or other malignant tumors in the brain.Type: ApplicationFiled: October 4, 2019Publication date: May 7, 2020Applicant: Board of Regents, the University of Texas SystemInventors: Michael J. McGINITY, Feng ZHANG, John R. FLOYD, James W. McGINITY
-
Publication number: 20200138708Abstract: Hollow fiber drug delivery devices are described. Device can contain structural or solid fibers. Fabric can be formed by fibers being interwoven or joined to each other. All or some of the fibers can be resorbable. Fibers can be subdivided, by deformations or closure points, into numerous compartments that separately deliver drug. Deformations can be located at points of fiber intersection or joining. Different drug or drug formulation can be provided in different places. Fibers can be given appropriate surface treatments or coatings to achieve desired properties such as wetting of pores and surfaces. Different release characteristics in different directions can be achieved. The hollow fibers can contain solid particles of drug, and can contain gel. Possible applications include hernia meshes, pouches, sutures, catheters, wound dressings, stents, nerve regrowth guides, refillable/drainable devices, and devices that deliver drug to lymphatic flow.Type: ApplicationFiled: December 12, 2019Publication date: May 7, 2020Inventors: Mohamed E. LABIB, Stanislav S. DUKHIN, Peter MATERNA, Jeffrey C. ROBERTSON, Ching-Yue LAI, Yacoob TABANI
-
Publication number: 20200138709Abstract: The invention relates to a pharmaceutical composition in the form of an aqueous solution, preferably a syrup, containing inosine pranobex and zinc gluconate, characterised in that it contains a sweetener selected from the group of disaccharides, preferably sucrose or/and from the group of polyols, preferably maltitol, a solubilizer from the group of hydroxy alcohols or mixtures thereof, preferably propylene glycol, glycerol, preservatives selected from the group of parahydroxybenzoic acid esters and mixtures thereof, preferably methyl parahydroxybenzoate, propyl parahydroxybenzoate, a sweetener, preferably sodium saccharine or sucralose, and pH regulators in the range from 5.7 to 12.0 preferably aroma, and a method of preparation thereof.Type: ApplicationFiled: June 21, 2018Publication date: May 7, 2020Inventors: Hanna WAHL, Marek DABROWA, Anna OSTROWSKA, Malgorzata KOWALSKA - PARTEKA, Jaroslaw PASINSKI, Arkadiusz MADEJCZYK
-
Publication number: 20200138710Abstract: The present invention provides compositions and methods for delivery of therapeutic agents across an barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which increases the flux of the therapeutic agent across the barrier, and a matrix forming agent. The matrix forming agent forms a gel at a suitable gelation temperature and has rheological properties for use in drug delivery, and in some cases, the gelation temperature and rheological properties are not significantly changed from those of the composition without the permeation enhancer. The invention also provides a matrix forming agent and compositions thereof. Such compositions are particularly useful in the treatment of infectious disease (e.g., otitis media). Methods of treatment, methods of delivery, and kits for the compositions described herein are also provided.Type: ApplicationFiled: September 14, 2017Publication date: May 7, 2020Applicant: Children's Medical Center CorporationInventors: Daniel S. Kohane, Rong Yang
-
Publication number: 20200138711Abstract: The invention relates to a hydrogel, in particular degradable or non degradable, comprising monomers of formula (I) and organosilica particles or porous silicon particles covalently bound thereto, optionally with non covalently bound organosilica and/or silicon particles mixed therewith, in particular degradable organosilica nanoparticles or core-shell nanocapsules; pharmaceutical, veterinary or cosmetic compositions thereof; and uses thereof as a medicament. The present invention finds applications in the therapeutic and diagnostic medical technical fields and also in cosmetic and veterinary technical fields.Type: ApplicationFiled: January 17, 2018Publication date: May 7, 2020Inventors: Luisa DE COLA, Giuseppe ALONCI, Silvana PERRETTA, Pietro RIVA, Federica FIORINI
-
Publication number: 20200138712Abstract: The present invention relates to the use of a liquid aqueous solution of edaravone in the treatment of an oxidative stress-mediated neurodegenerative disorder in a human patient, said treatment comprising at least once daily oral administration of the liquid edaravone solution to the human patient, to provide a daily dose of 40-120 mg edaravone during an uninterrupted period of at least 10 days. Examples of oxidative stress-mediated neurodegenerative disorders that can be treated in this way include amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), cerebral amyloid angiopathy (CAA), Alzheimer's disease and Parkinson's disease.Type: ApplicationFiled: January 3, 2020Publication date: May 7, 2020Inventors: Ronald VAN DER GEEST, Sytske Hyke MOOLENAAR
-
Publication number: 20200138713Abstract: A medical device for making foam includes a syringe having a plunger for dispensing a liquid from a liquid dispensing port, and a mixing chamber including a mixing chamber inlet, a mixing chamber outlet, a liquid flow channel extending between the mixing chamber inlet and the mixing chamber outlet, and a gas inlet channel that intersects with the liquid flow channel. The system has a gas cartridge containing the gas, a first gas conduit connected with the syringe, and a second gas conduit connected with the gas inlet channel. An actuator is coupled with the gas cartridge for releasing the gas into the first and second gas conduits. The released gas in the first gas conduit forces the plunger toward the liquid dispensing port for dispensing the liquid from the liquid dispensing port and into the liquid flow channel while the released gas in the second gas conduit flows into the gas inlet channel of the mixing chamber for mixing with the liquid in the liquid flow channel.Type: ApplicationFiled: November 5, 2018Publication date: May 7, 2020Inventors: Nicole Smith, Michael Cardinale
-
Publication number: 20200138714Abstract: The invention relates to flat dosage forms that disintegrate or dissolve in an aqueous environment and release at least one active ingredient in a body orifice or body cavity. The inventive dosages are formed from a polymer matrix in the form of a solidified foam having cavities and contain at least one pharmaceutical active ingredient. The inventive dosage forms further have a high mass per unit area in the region of 50 to 350 g/m2. Despite their high mass per unit area and the resulting high active ingredient loading during administration, these dosage forms exhibit a substantially improved mouthfeel in comparison to conventional film dosage forms. The invention also relates to methods for producing a dosage form of this type.Type: ApplicationFiled: June 7, 2018Publication date: May 7, 2020Inventors: Markus MÜLLER, Marius BAUER, Michael LINN
-
Publication number: 20200138715Abstract: Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.Type: ApplicationFiled: May 15, 2017Publication date: May 7, 2020Applicants: Infectious Disease Research Institute, University of Virginia Patent FoundationInventors: Christopher B. Fox, Susan S. Lin, Darrick Carter, Neal Van Hoeven, Mayuresh M. Abhyankar, William A. Petri
-
Publication number: 20200138716Abstract: Nanoparticle mediated microvascular embolization (NME) of tumor tissue may occur after systemic administration of PEM as a result of the nitric oxide sequestration by PEM. Nitric oxide sequestration may cause a reduction in available extracellular nitric oxide in the tumor endothelium, which may prompt a widespread shutdown of vascular flow, hemorrhage, and necrosis. In particular, shutdown of vascular flow may trigger changes in nitric oxide production as well as trigger an acute inflammatory response, which may create reactive nitrogen species that are particularly destructive to the microvasculature. PEM constructs are developed that incorporate large amounts of iron-containing protein, possess high oxygen affinities, and demonstrate delayed nitric oxide binding. Such properties induce selective NME of tumors after extravasation, and will likely enhance the effect of VEGFR TKIs and/or mTOR inhibitors.Type: ApplicationFiled: November 6, 2019Publication date: May 7, 2020Inventor: P. Peter GHOROGHCHIAN
-
Publication number: 20200138717Abstract: Disclosed herein are pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. The pharmaceutical formulations are stable and ready-to-use liposomes for the treatment of emesis and are particularly useful for treatment of chemotherapy or surgery-induced nausea and vomiting. Methods of preparation of the aprepitant formulations are also provided.Type: ApplicationFiled: June 26, 2018Publication date: May 7, 2020Applicant: ForDoz Pharma Corp.Inventors: Sydney Ugwu, Xin He, Zengli Fu, Xin Teng, Ming Ji
-
Publication number: 20200138718Abstract: Dermal delivery compositions are provided. Aspects of the dermal delivery compositions include the presence of active agent-calcium phosphate particle complexes, where these complexes include uniform, rigid, spherical nanoporous calcium phosphate particles associated with one or more active agents. Also provided are methods of using the compositions in active agent delivery applications.Type: ApplicationFiled: June 3, 2019Publication date: May 7, 2020Inventor: Zahra Mansouri
-
Publication number: 20200138719Abstract: The present invention relates to a granular composition comprising essentially Tenofovir, wherein the composition is devoid of an excipient. Tenofovir granules of the present invention are prepared in twin-screw processor such that the content of total impurities in the prepared granules is less than 2.0%.Type: ApplicationFiled: January 6, 2020Publication date: May 7, 2020Applicant: STEERLIFE INDIA PRIVATE LIMITEDInventors: Indu BHUSHAN, Vinay RAO, Radhika GHIKE
-
Publication number: 20200138720Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: October 29, 2019Publication date: May 7, 2020Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20200138721Abstract: Described herein is a method for forming multi-layer drug dosage forms having at least two layers. In the method, a first formulation comprising a non-gelling matrix forming agent and having a first density is dosed into a preformed mold. A second formulation comprising a non-gelling matrix former and having a second density not equal to the first density is subsequently dosed into the preformed mold. Then, the combination of the formulations dosed into the mold is freeze dried to form the multi-layer dosage form having at least two layers. The use of a density difference between the first and second formulations ensures formation of a product with two distinct layers.Type: ApplicationFiled: October 25, 2017Publication date: May 7, 2020Applicant: Catalent U.K. Swindon Zydis LimitedInventors: Leon Paul GROTHER, Keiko TSUTSUMI, Rosaleen Theresa MCLAUGHLIN, Yik Teng WONG
-
Publication number: 20200138722Abstract: The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension. The present invention restores altered probiotic organism imbalances that are characteristic of said diseases among others as well as defines a platform technology development for site specific delivery of probiotic organisms in the GI tract of a mammal, most specifically the ileum and/or right colon of a human subject.Type: ApplicationFiled: June 19, 2019Publication date: May 7, 2020Inventors: Mohan Kabadi, Jerome J. Schentag
-
Publication number: 20200138723Abstract: A composition for manufacture of hard hydroxypropyl methyl cellulose capsules comprising a film forming material of hydroxypropyl methyl cellulose having a methoxy content of 27.0-30.0% (w/w), and a hydroxypropoxy content of 4.0-7.5% and as a 2% weight solution, a viscosity of 3.5-6.0 cPs at 20° C. dipping compositions, process for manufacture of hard hydroxypropyl methyl cellulose capsules according to a dip coating process and hard capsule shells.Type: ApplicationFiled: January 8, 2020Publication date: May 7, 2020Applicant: Capsugel Belgium NVInventors: Dominique Nicolas Cade, David He Xiongwei
-
Publication number: 20200138724Abstract: Crystalline microparticles consisting of a phenylalkylamino beta2-adrenergic agonist coated with a C12-C20 fatty acid are useful for the preparation of pharmaceutical aerosol formulations in form of suspension in a liquefied propellant gas or powder formulations.Type: ApplicationFiled: January 9, 2020Publication date: May 7, 2020Applicant: Chiesi Farmaceutici S.p.A.Inventors: Gaetano BRAMBILLA, Paolo Colombo, Francesca Buttini, Michele Miozzi
-
Publication number: 20200138725Abstract: A composition for injection into a host is provided according to the embodiments of the present application. The composition consists of microparticles consisting essentially of an opioid antagonist and a polymeric binder selected from the group consisting of poly(glycolic acid), poly-d,l-lactic acid, poly-l-lactic acid, copolymers of the foregoing, poly(aliphatic carboxylic acids), copolyoxalates, polycaprolactone, polydioxanone, poly(ortho carbonates), poly(acetals), poly(lactic acid-caprolactone), polyorthoesters, poly(glycolic acid-caprolactone), polyanhydrides, and polyphosphazines; an injection vehicle, wherein said injection vehicle consists of water, a viscosity enhancing agent, a wetting agent, and a tonicity adjusting agent; and a steroidal anti-inflammatory agent.Type: ApplicationFiled: January 6, 2020Publication date: May 7, 2020Inventor: Lance L. GOOBERMAN
-
Publication number: 20200138726Abstract: A composition includes sintered nanoparticles prepared by sintering a chelate of ferrous ions with an amino acid. The sintered nanoparticles have an average particle diameter ranging from 10 to 400 nm as determined by Electron Probe X-ray Micro-Analyzer. Also disclosed herein are a method for inhibiting and/or killing a virus in a subject and applications of such method. The method includes administering to the subject the composition.Type: ApplicationFiled: December 27, 2019Publication date: May 7, 2020Inventors: Tsun-Yuan LIN, Mu-Kuei CHEN, Kai-Ting WANG, Hsun-Jin JAN
-
Publication number: 20200138727Abstract: The present invention provides high density lipoprotein (HDL) or reconstituted HDL (rHDL) particles for the delivery of non-nucleic acid therapeutic agents, therapeutic agents or nucleic acids to cells and tissues. The use of HDL or rHDL particles has advantages over other delivery systems because they are smaller in size and their contents are rapidly internalized by receptors of specific cells, including receptors on the surface of tumor tissue. The HDL or rHDL nanoparticles of the present invention may include a positively charged polyamino acid, which neutralizes the negatively charged nucleic acid, thus allowing for successful incorporation of the nucleic acid into an HDL or rHDL particle. Methods of delivering therapeutic agents to cells and target tissues using the disclosed HDL or rHDL particles are provided as are methods of treating various diseases and disorders.Type: ApplicationFiled: April 20, 2018Publication date: May 7, 2020Inventors: ANDRAS G. LACKO, NIRUPAMA A. SABNIS, SUNIL SHAH, LINDA K. MOOBERRY
-
Publication number: 20200138728Abstract: Cationic polymers are provided for delivering anionic active agents, preferably in the form or nanoparticles and other nanostructures. The polymer can be a polycation homopolymer or a copolymer containing a polycation block. The polycations and polycation containing polymers can contain dicarboxylic acid ester units and units of (?-amino acid)-?,?-alkylene diester units. The nanoparticles can contain high loadings of anionic active agents, with sustained release of the active agents. Methods of making the polycations and polycation containing polymers are provided. Methods of making the nanoparticles and formulating them for administration to an individual in need thereof are also provided.Type: ApplicationFiled: January 2, 2020Publication date: May 7, 2020Inventors: Omid Farokhzad, Jun Wu, Lili Zhao
-
Publication number: 20200138729Abstract: Provided herein are implantable compositions and methods of use thereof for the local delivery of therapeutically active agents.Type: ApplicationFiled: November 11, 2019Publication date: May 7, 2020Inventors: John Schwartz, Aaron Henry Colby
-
Publication number: 20200138730Abstract: Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive log P. The method involves dispersing the lipophilic active(s) in a carrier oil and uniformly distributing them as emulsified oil droplets into a polymer matrix. The methods reported here produce oral films containing a stable emulsion with up to 40% oil phase. The oil phase consists of the carrier oil and lipophilic active(s). This offers the possibility to enhance the amount of lipophilic actives to be included in the film formulation while preserving the film characteristics. The resulting oral films offer a standardized dosage form for lipophilic actives as well as easier and more convenient administration, transportation, handling, and storage.Type: ApplicationFiled: April 15, 2019Publication date: May 7, 2020Applicant: Intelgenx Corp.Inventors: Carolin Madwar, Nadine Paiement, Rodolphe Obeid, Justin Conway, Erick Gonzalez-Labrada
-
Publication number: 20200138731Abstract: To provide a phosphatidylcholine transdermal absorption preparation containing phosphatidylcholine in an adhesive layer. A phosphatidylcholine transdermal absorption preparation has a configuration in which an adhesive layer formed on at least one side of a support contains phosphatidylcholine, an adhesive component, and a lipophilic component, and thus the preparation becomes a patch-type transdermal absorption preparation which acts as a fat-decreasing agent which contains phosphatidylcholine and can exert an effect that local obesity such as subcutaneous fat is dissolved and fat is decreased by transdermal absorption of phosphatidylcholine as the preparation is pasted to the skin of a human body since phosphatidylcholine can be stably present in the adhesive layer and has an advantage due to the patch dosage form that the preparation can be fixed to the affected area and is more favorably handled as compared to liquid preparations and the like.Type: ApplicationFiled: April 27, 2018Publication date: May 7, 2020Applicant: UNISH INC.Inventor: Hirofumi NAKANISHI
-
Publication number: 20200138732Abstract: An adhesive skin patch with a support liner comprises at least a strip drug product and a release liner longer than the drug product. The support liner includes a backing film and an adhesive layer; the drug product is quadrilateral with two long sides being straight in parallel and two short sides each elliptical arcs convex outward; a longest interval between the two short sides is 20.0 mm or more and 50.0 mm or less, and an interval between the two long sides is 5.0 mm or more and 37.5 mm or less; and the elliptical arc has: an ellipse major axis of 20.0 mm or more and 50.0 mm or less, an ellipse minor axis of 14.8 mm or more and less than 50.0 mm, and the minor axis of at least 2.0 mm wider than the interval of the two long sides.Type: ApplicationFiled: June 22, 2018Publication date: May 7, 2020Inventors: Takao HIRAOKA, Atsushi MURATA, Koji KAWAHARA, Takahiro OGAWA, Akiharu ISOWAKI
-
Publication number: 20200138733Abstract: An active molecule delivery system whereby active molecules can be released on demand and/or a variety of different active molecules can be delivered from the same system and/or different concentrations of active molecules can be delivered from the same system. The active delivery system includes a plurality of microcells, wherein the microcells are filled with a medium including active molecules. The microcells include an opening, and the opening is spanned by a porous diffusion layer. The microcell arrays may be loaded with different active ingredients, thereby providing a mechanism to deliver different, or complimentary, active ingredients on demand.Type: ApplicationFiled: January 3, 2020Publication date: May 7, 2020Inventor: Lei LIU
-
Publication number: 20200138734Abstract: A topical formulation for treating bruising can include a protein denaturant, preferably 2-butanol, a penetration enhancer, preferably a combination of dimethyl isosorbide and propylene glycol, and water. The topical formulation can be particularly effective for reversing bruising caused by Senile Purpura and/or preventing hemosiderin staining.Type: ApplicationFiled: December 27, 2019Publication date: May 7, 2020Inventor: Jerry McSHANE
-
Publication number: 20200138735Abstract: Systems and methods provide sugar alcohol to heat stressed ruminants to improve performance. During periods of high temperature or humidity, heat stressed ruminants may exhibit decreased dry matter intake, and in response, an effective amount of sugar alcohol such as sorbitol may be provided in the ruminant diet to cause performance to increase, which may include increased milk yield, improved feed efficiency or both compared to heat stressed dairy cattle without sugar alcohol in the diet.Type: ApplicationFiled: January 3, 2020Publication date: May 7, 2020Applicant: PURINA ANIMAL NUTRITION LLCInventors: Bill L. Miller, Jill A. Davidson, Cindie M. Luhman
-
Publication number: 20200138736Abstract: Cannabidiol (CBD) formulation comprising a mixture of full spectrum cannabidiol oil (FSO) and cannabidiol isolate (CBD isolate) is disclosed. The formulation contains a total amount of CBD derived from a combination of an amount of CBD in the FSO and an amount of CBD from the CBD isolate. The formulation of FSO and CBD isolate in used for medicinal and health benefits in a wide range of products, such as tinctures, capsules, creams or lotions, bath salts or bombs, soaps, pet or animal tinctures, and pet or animal edible chews.Type: ApplicationFiled: August 29, 2019Publication date: May 7, 2020Applicant: Healthy Roots Inc.Inventor: Elizabeth Merritt
-
Publication number: 20200138737Abstract: The present technology generally relates to compositions comprising cannabinoids for relieving pain in a subject and to methods of using such compositions for relieving pain in a subject.Type: ApplicationFiled: November 1, 2019Publication date: May 7, 2020Inventors: Mark Andrew HETHERINGTON, Chris Schnarr
-
Publication number: 20200138738Abstract: The present invention relates in the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Surge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.Type: ApplicationFiled: January 8, 2020Publication date: May 7, 2020Inventors: Geoffrey GUY, Stephen WRIGHT, Alice MEAD, Anne COMI